CLINICAL AND RESEARCH REPORTS Conventional vs. Newer Antipsychotics in Elderly Patients Dilip V. Jeste, M.D. Enid Rockwell, M.D. M. Jackuelyn Harris, M.D. James B. Lohr, M.D. Jonathan Lacro, Pharm.D. Elderly patients with schizophrenia and dementia patients with agitation are frequently candidates for antipsychotic treatment. Conventional neuroleptics have relatively little effect on negative symptoms and may cause considerable side effects, especially in elderly patients. The authors have found a 29% cumulative annual incidence of tardive dyskinesia (TD) in middle-aged and elderly outpatients treated with relatively low doses of conventional neuroleptics. Newer antipsychotics are less likely to cause extrapyramidal symptoms and may be associated with a lower risk of TD. They are generally effective for both positive and negative symptoms and may also improve some aspects of cognition, but these drugs have their own side effects. Dosing requirements for elderly patients tend to be much lower than those for younger adults. (Am J Geriatr Psychiatry 1999; 7:70–76) A s the population in the United States continues to age, physicians must become increasingly familiar with the health care needs of elderly patients. Psychiatrists will be caring for more patients with late-life psychotic disorders and those with behavioral disorders associated with Alzheimer’s disease (AD) and other dementing illnesses. Although the symptoms of some mental illnesses respond to cognitive–behavior therapy and other nonpharmacologic interventions, antipsychotic drugs remain the principal means of treating psychotic and certain other severe behavioral symptoms, both in younger and older patients. For many years, the choice of antipsychotic medication was limited to what are now called conventional or typical neuroleptics, such as haloperidol and thioridazine. Today, clinicians also can select from newer or atypical antipsychotics, such as clozapine, risperidone, olanzapine, and quetiapine. Choosing the appropriate medication and its dosing requires careful consideration of each drug’s effects, including its side effects. Conventional or Typical Neuroleptics Conventional neuroleptics have been available for more than 45 years, beginning with the introduction of the low-potency agent chlorpromazine in 1952. Highpotency neuroleptics, such as haloperidol, and intermediate-potency ones, such as loxapine, became available later on. All these drugs share a common characteristic in that they block the dopamine (especially D2) receptors in the brain. This activity confers both benefits and drawbacks. Although conventional neuroleptics are effective for the positive symptoms of schizophrenia, they have relatively little effect on the negative symptoms of this disease. They also can cause side effects, many of which are of particular concern in elderly patients, who are more susceptible to drug side effects. Neuroleptic side effects include sedation, anticholinergic toxicity (which can result in urinary retention, constipation, dry mouth, glaucoma, and confusion), extrapyramidal symptoms ([EPS]; e.g., parkinsonism, akathisia, and dystonia), and tardive dyskinesia (TD). TD can be troubling because of its frequently persistent nature. In young adult patients taking conventional neuroleptics, the annual cumulative incidence of TD is 4% to 5%.1 To determine the incidence of this side effect in middle-aged and elderly subjects, we studied 439 outpatients (with a mean age of 65 years) in whom antipsychotic treatment was indicated (Figure 1). Earlier reports from our group2,3 had included 266 and 307 of these patients, respectively. Twenty-eight percent of the patients had a primary diagnosis of dementia with psychotic symptoms or other severe behavioral disturbances; 22% had schizophrenia; 18% had a mood disorder; and the remainder had other diagnoses. At the time of study enrollment, a majority of the patients had Received February 24, 1997; revised August 10, 1997; accepted August 11, 1997. From the Department of Psychiatry, University of California, San Diego, and the San Diego Veterans Affairs Medical Center. Address correspondence to Dr. Jeste, Psychiatry Service, 116A1, Veterans Affairs Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, e-mail: Dilip_Jeste@GP-Post.ucsd.edu 70 Am J Geriatr Psychiatry 7:1, Winter 1999 Jeste et al. been treated with neuroleptics for less than 1 month; the median duration of lifetime antipsychotic drug exposure was 27 days. After study enrollment, most of the patients were treated with conventional neuroleptics, mainly haloperidol or thioridazine, at relatively low doses (usually less than 150 mg chlorpromazine-equivalent daily). Patients were assessed at baseline, 1 month, 3 months, and every 3 months thereafter. The diagnosis of TD was based on the Schooler-Kane4 criteria, using the Abnormal Involuntary Movement Scale (AIMS).5 With 12 months of neuroleptic treatment, TD developed in 28.8% (95% confidence interval [CI]: 26.1%– 31.5%) of the patients. At 24 and 36 months, the mean (with 95% CI) cumulative incidence of this side effect was 50.1% (46.7%–53.5%) and 63.1% (59.3%–66.9%), respectively, demonstrating the higher risk of TD in middle-aged and elderly patients even with low doses of conventional neuroleptics. By discontinuing neuroleptic treatment, TD may be avoided or reversed. In patients with behavioral disturbances of dementia, drug withdrawal or at least dose reduction does not present major problems in a majority of cases;6 indeed, in appropriate patients, neuroleptics may be slowly tapered after a few months to deter- mine whether they are still needed to control the behavioral symptoms. In patients with schizophrenia, however, drug withdrawal is usually difficult. A recent literature review of 66 studies including a total of 4,356 patients with schizophrenia or schizoaffective disorder showed that relapse rate over a mean follow-up period of 9.7 months was 53% when the antipsychotic drugs were withdrawn and 16% when the drugs were maintained.7 Although most of these studies were conducted in young adults with schizophrenia, the rates of relapse after neuroleptic withdrawal appeared to be similar in the investigations that involved elderly patients.8 With conventional neuroleptics, clinicians face the following dilemma: to continue using a drug associated with serious side effects or discontinue the drug and possibly trigger a relapse. Maintaining patients on flexible, individualized, low doses of conventional neuroleptics may prevent or delay the appearance of side effects while continuing to control the psychotic symptoms. Another possible solution is to prescribe newer antipsychotic medications, which are usually more effective and have fewer side effects than conventional neuroleptics. Newer or Atypical Antipsychotics FIGURE 1. Incidence of tardive dyskinesia (TD) in 439 middle-aged and elderly outpatients (age Ͼ45) over a 36-month period: means with 95% confidence intervals (CI) Am J Geriatr Psychiatry 7:1, Winter 1999 At present, four newer antipsychotic drugs—clozapine, risperidone, olanzapine, and quetiapine—have been approved for use in the United States. Several other newer antipsychotics, including ziprasidone and zotepine are currently awaiting Food and Drug Administration (FDA) approval. Unlike conventional neuroleptics, the atypical ones are potent central serotonin antagonists in addition to being central dopamine-receptor antagonists. This activity profile apparently confers several advantages with respect to both efficacy and safety. In young and middleaged patients with schizophrenia, serotonin–dopamine antagonists have generally been shown to be effective for both the positive and negative symptoms of the disease.9–12 These drugs are associated with a lower incidence of EPS than conventional neuroleptics. The low risk of TD in patients taking clozapine is well established.13 The incidence of TD with other atypical antipsychotics is also likely to be lower than that with conventional neuroleptics, given that EPS has been found to be a risk factor for TD in elderly patients.2,14 Nonetheless, the determination of exact risk of TD with these newer drugs requires long-term studies. An intriguing 71 Conventional vs. Newer Antipsychotics aspect of the atypical antipsychotics is their potential for enhancing cognition, a particularly useful effect in older patients with schizophrenia. In the following discussion, we will refer only to published articles, rather than to abstracts or presentations. Clozapine. Although clozapine has been available in the United States since the late 1980s,9 well controlled published studies of its use in elderly patients have been rare. Data from open, uncontrolled trials in older psychiatric patients indicate that clozapine is useful for controlling treatment-resistant psychotic symptoms and managing patients with severe TD.15,16 Although clozapine is effective in elderly patients, side effects limit its use in this patient population. Patients taking this drug are at risk for leukopenia and even agranulocytosis; this risk necessitates weekly blood monitoring. Elderly outpatients may have difficulty complying with the need for weekly blood draws. Clozapine can lower the seizure threshold and can also cause sedation and confusion. In patients with dementia or glaucoma or in men with prostatic hypertrophy, the anticholinergic side effects of this drug can be particularly troublesome. Despite its side effects, clozapine may be indicated for some elderly patients, such as Parkinson’s disease patients with psychotic symptoms,17,18 patients with chronic psychotic disorders that do not respond to other antipsychotic medications, or those with severe TD. For these patients, recommended starting doses are much lower than those for younger patients: 6.25 mg to 12.5 mg/day, with increases of no more than 6.25 mg to 12.5 mg once or twice a week. Maintenance doses should generally be 50 mg to 100 mg/day. Risperidone. Beginning with the report by Marder and Meibach,10 numerous published double-blind investigations have established the significantly better efficacy and tolerability of risperidone compared with haloperidol in younger adults. Although published data from double-blind, placebo-controlled trials of risperidone in elderly patients are not yet available, we have studied risperidone in open studies of patients age 45 to 100 years.19 Most enrolled patients had schizophrenia or related psychoses, such as delusional disorder, and the rest had psychotic symptoms associated with dementia. Patients received low doses of risperidone, usually less than 3 mg/day. Of the 53 enrolled patients, 40 (76%) experienced a noticeable improvement of symptoms. 72 Improvement in the positive symptoms of schizophrenia, such as delusions and hallucinations, was apparent within the first 6 weeks after treatment was started. Negative-symptom (e.g., social withdrawal, blunted affect, and apathy) improvement was apparent only after 6 to 10 weeks of treatment. We have reviewed the literature elsewhere19,20 on the use of risperidone in elderly patients. We also examined the effects of risperidone on global cognition in 19 of our patients, most with schizophrenia.19 The mean age (עstandard deviation [SD]) of the patients was 65 41עyears. Treatment with risperidone for a mean of 11 7עweeks was associated with a significant increase in the mean Mini-Mental State Exam (MMSE)21 score (24 before treatment to 28 after treatment; P .)500.0סInterestingly, open-label treatment with conventional neuroleptics given for 3 months in relatively low dosages to 37 age-, gender-, and diagnosiscomparable patients in our population resulted in no significant change in the mean MMSE scores.22 Berman and colleagues23 have also reported cognitive improvement with low-dose risperidone given to elderly psychotic patients in an open trial. In a recent report on younger adults with chronic schizophrenia, Green and colleagues24 found significant improvement in performance on tests of verbal working memory with risperidone, as compared with haloperidol. Such findings do not necessarily suggest that risperidone directly enhances cognition in patients with schizophrenia. The effects on cognition may be indirect, resulting from its favorable effects on the positive and negative symptoms of schizophrenia and its low incidence of EPS at the doses used in these studies. Nonetheless, a positive effect on cognition may be of particular importance in light of recent data suggesting an association between cognitive performance and functioning in daily life.25,26 It is interesting to note that the cognitive effects of clozapine have been reported to be somewhat mixed. Whereas performance on tests of verbal fluency and graphomotor speed was improved, there was significant worsening of the visual memory and executive, frontal ability.27 The likely explanation is that clozapine, as an atypical antipsychotic, may improve cognition, but its high anticholinergic and frontal D1 receptor-blocking activity may serve to impair certain aspects of neuropsychological performance, but there is no evidence to suggest that any of the atypical antipsychotics affect cognition in patients with dementia. The more common side effects associated with ris- Am J Geriatr Psychiatry 7:1, Winter 1999 Jeste et al. peridone use in elderly patients are postural hypotension, sedation, and EPS. These side effects (especially EPS) are dose-related, suggesting a need for caution in raising the dose. Starting and maintenance dosages of risperidone in elderly patients are much lower than those recommended for younger patients. A starting dose of 0.25 mg to 0.5 mg/day is appropriate for older patients. The dose should be increased by no more than 0.25 mg to 0.5 mg once or twice per week, generally up to a maximum daily dosage of 1.0 to 2.5 mg. Patients with dementia, Parkinson’s disease, or significant hypotension should usually not receive more than 1 mg/day of risperidone. Other Atypical Antipsychotics The published data on other atypical antipsychotics in elderly patients are limited. Olanzapine. Olanzapine was approved by the FDA for clinical use late in 1996. A number of double-blind, controlled studies, such as an international collaborative trial involving nearly 2,000 mostly young and middleaged adults28 have shown a superior and broaderspectrum efficacy of olanzapine in the treatment of schizophrenia, schizoaffective, and schizophreniform disorders, along with a significantly better safety profile than haloperidol. There is also one report of lower incidence of TD with olanzapine than with haloperidol among non-elderly patients.29 The main side effects of olanzapine include sedation, dizziness, weight gain, and minimal anticholinergic reactions. The published data with olanzapine in elderly patients are, however, restricted. In one open-label study,30 15 parkinsonian patients (without dementia) with drug-induced psychosis were treated successfully with olanzapine at doses of 1 mg to 15 mg/day (mean: 7 mg). One patient discontinued treatment because of drowsiness. We recommend that the starting dose of olanzapine in elderly patients be 1 mg to 5 mg (average 2.5 mg) daily, and the maintenance dose be 5 mg to 15 mg daily. Quetiapine. Quetiapine was introduced into clinical practice in 1997. It has been found, in large-scale, double-blind investigations, to be significantly more effective and better tolerated than haloperidol in patients with schizophrenia.31 It has an exceptionally low potential for EPS even at higher doses and little anticholin- Am J Geriatr Psychiatry 7:1, Winter 1999 ergic or prolactin-elevating action. The principal adverse effects include drowsiness, postural hypotension, and (in long-term studies of dogs, but not reported in humans) lenticular opacities. To date, several abstracts but no published articles on quetiapine in elderly patients are available. On the basis of the clinical literature, the recommended starting doses of quetiapine in elderly patients would be 12.5 mg to 25 mg daily, with the optimal target dose being 75 mg to 125 mg per day. Others. A number of other novel antipsychotic agents are currently in various stages of investigation. Some of these, such as ziprasidone, are expected to be approved shortly. At this time, published articles on the use of these drugs in the geriatric population are practically nonexistent. Table 1 summarizes the recommended starting and maintenance doses (for elderly patients) of the two most commonly prescribed conventional neuroleptics and the four currently available atypical antipsychotics. It is expected that there will be an increasing number of investigations of the efficacy and tolerability of the various atypical antipsychotics in geriatric patients, including studies with double-blind design and large sample sizes. Switching From a Conventional Neuroleptic to a Newer Antipsychotic Because of its side effects, clozapine is used in psychiatry predominantly for patients with treatment-resistant schizophrenia or severe TD. Other atypical antipsychotics, such as risperidone, olanzapine, or quetiapine, TABLE 1. Usual recommended doses of common antipsychotic drugs for elderly patients, mg/day Antipsychotic Starting Dose Maintenance Dose Haloperidol Thioridazine Clozapine Risperidone Olanzapine Quetiapine 0.25–0.5 10–25 6.25–12.5 0.25–0.5 1–5 12.5–25 1–3.5 50–100 50–100 1–2.5 5–15 75–125 Note: Patients with major comorbidity, such as dementia or other serious physical illnesses, would need doses at the lower end of the respective ranges, whereas patients with early-onset schizophrenia without significant comorbidity would require doses at the higher end of the ranges. The recommended doses represent averages. Individual patients may need lower or higher doses than those shown here. 73 Conventional vs. Newer Antipsychotics should, however, also be considered for patients who require antipsychotic treatment for the first time. Newer antipsychotics are also indicated when patients do not respond to conventional neuroleptics or experience distressing side effects. The method for switching from a conventional neuroleptic to a newer atypical antipsychotic depends on the reason for the switch (Figure 2). (Needless to say, such a switch may not be warranted in a patient who has responded optimally to a conventional neuroleptic without side effects and who only needs neuroleptic treatment for a relatively short period.) A: If the conventional neuroleptic is ineffective, the dose of the current drug should be maintained while that of the newer antipsychotic is slowly in- FIGURE 2. 74 B: creased until the optimal maintenance dose is reached. At that point, the dose of the conventional neuroleptic can be slowly decreased and ultimately discontinued. For patients with moderate or distressing side effects, such as EPS, the dose of the conventional neuroleptic should be slowly tapered while the dose of the newer antipsychotic is slowly increased. Thus, in both scenarios, A and B (see Figure 2), the conventional neuroleptic should not be stopped suddenly; otherwise, there may be a risk of relapse. In all cases in which a patient was receiving an anticholinergic drug along with the conventional neuroleptic, the anticholinergic agent may be continued for a few days after the neuroleptic-withdrawal. This reduces the Suggested methods of switching from a conventional neuroleptic to a newer, atypical antipsychotic, according to the reason for the switch Am J Geriatr Psychiatry 7:1, Winter 1999 Jeste et al. chances of cholinergic rebound, with resultant nausea, vomiting, and other symptoms. C: If a patient is experiencing life-threatening side effects, such as neuroleptic malignant syndrome, the offending neuroleptic drug must be discontinued immediately. The newer antipsychotic may then be started and slowly titrated to the most effective dose. Whenever possible, once-daily dosing is preferred to a multiple daily dosing regimen. Oncedaily dosing increases the likelihood of compliance, particularly in patients with chronic schizophrenia, who typically require antipsychotic medication for most of their life. Patients taking medication once daily are, however, at an increased risk for side effects such as sedation or postural hypotension after drug administration during the first few days. To reduce this problem, the clinician may prescribe smaller, divided doses initially, then switch to a once-daily regimen after a steady-state drug level is achieved. Pharmacoeconomics The atypical antipsychotics are more expensive than the conventional drugs. At the same time, studies in younger adults show that the newer agents may be more cost-effective in the longer term because they reduce the number and length of hospitalizations.32 Furthermore, the lower incidence of EPS and probably of TD may result in better compliance and an improved quality of life for the patients. Thus, the overall cost– benefit ratio would usually seem to favor the atypical antipsychotics over the typical ones. There is, however, a need for well-designed pharmacoeconomic studies comparing typical and atypical antipsychotics, as sug- gested by Hargreaves and Shumway,33 especially for elderly patients. CONCLUSIONS The availability of the newer atypical antipsychotic drugs offers clinicians an additional means of treating the symptoms of schizophrenia and other psychotic disorders as well as severe behavioral disturbances in patients with dementia. These drugs may be particularly appropriate for elderly patients, who are more susceptible to EPS and TD associated with conventional agents. The different atypical antipsychotics do have their own side effects and other limitations. Clinicians who prescribe antipsychotics for elderly patients should start with a low initial dose, increasing this dose slowly until the lowest effective dose is reached. Polypharmacy is also a concern among elderly patients, who are often being treated for various medical problems. Clinicians should try to avoid prescribing multiple drugs with anticholinergic or sedative effects. It is important to remember that although antipsychotics provide symptomatic relief, they do not cure the underlying illness. Thus a comprehensive treatment approach for psychotic and other severe behavioral disorders must combine drug therapy with appropriate psychosocial interventions. This work was presented, in part, at the symposium, “Pharmacotherapy and the Geriatric Patient,” held at the 149th Annual Meeting of the American Psychiatric Association, May 5, 1996, New York, NY. The work was supported, in part, by National Institute of Mental Health grants MH49671, MH45131, MH43693, MH51459, and by the Department of Veterans Affairs. References 1. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8:52S– 56S 2. Jeste DV, Caligiuri MP, Paulsen JS, et al: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52:756–765 3. Jeste DV, Rockwell E, Harris MJ, et al: Incidence of tardive dyskinesia in early stages of treatment with typical neuroleptics in older patients. Am J Psychiatry (in press) 4. Schooler N, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486–487 5. National Institute of Mental Health: Abnormal Involuntary Move- Am J Geriatr Psychiatry 7:1, Winter 1999 ment Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom 1975; 4:3–6 6. Harris MJ, Heaton RK, Schalz A, et al: Neuroleptic dose reduction in older psychotic patients. Schizophr Res 1997; 27:241–248 7. Gilbert PL, Harris MJ, McAdams LA, et al: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52:173– 188 8. Jeste DV, Lacro JP, Gilbert PL, et al: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993; 19:817–830 9. Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796 75 Conventional vs. Newer Antipsychotics 10. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835 11. Meltzer HY, Fibiger HC: Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology 1996; 14:83–85 12. Small JG, Hirsch SR, Arvanitis LA, et al: Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997; 54:549–557 13. Kane JM, Woerner MG, Pollack S, et al: Does clozapine cause tardive dyskinesia?. J Clin Psychiatry 1993; 54:327–330 14. Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402–2406 15. Salzman C, Vacarro B, Lieff J, et al: Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3:26–33 16. Chengappa KNR, Baker RW, Kreinbrock SB, et al: Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995; 8:12–15 17. Kahn N, Freeman A, Juncos JL, et al: Clozapine is beneficial for psychosis in Parkinson’s disease. Neurology 1991; 41:1699–1700 18. Factor SA, Brown D: Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disord 1992; 7:125–131 19. Jeste DV, Eastham JH, Lacro JP, et al: Management of late-life psychosis. J Clin Psychiatry 1996; 57(suppl 3):39–45 20. Jeste DV, Eastham JH, Gierz M, et al: Use of risperidone in the elderly, in The Art of Rational Risperidone Therapy. Edited by Ayd FJ. Baltimore, MD, AYD Medical Communications, 1997, pp 147– 167 21. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198 22. Jeste DV, Lohr JB, Eastham JH, et al: Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res (in press) 23. Berman I, Merson A, Rachov-Pavlov J, et al: Risperidone in elderly 76 schizophrenic patients: an open-label trial. Am J Geriatr Psychiatry 1996; 4:173–179 24. Green MF, Marshall BD, Wirshing WC, et al: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154:799–804 25. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321–330 26. Klapow JC, Evans J, Patterson TL, et al: Direct assessment of functional status in older patients with schizophrenia. Am J Psychiatry 1997; 154:1022–1024 27. Hoff AL, Faustman WO, Wieneke M, et al: The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996; 15:361–369 28. Tollefson GD, Beasley CM, Tran PV, et al: Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457–465 29. Tollefson GD, Beasley CM, Tamura RN, et al: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248–1254 30. Wolters EC, Jansen ENH, Tuynman-Qua HG, et al: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47:1085–1087 31. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group: Multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233–246 32. Meltzer HY, Cola P, Way L, et al: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630–1638 33. Hargreaves WA, Shumway M: Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57:66–76 Am J Geriatr Psychiatry 7:1, Winter 1999